Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002802808 | SCV003593370 | uncertain significance | Inborn genetic diseases | 2024-07-25 | criteria provided, single submitter | clinical testing | The c.5149T>A (p.C1717S) alteration is located in exon 40 (coding exon 39) of the CDH23 gene. This alteration results from a T to A substitution at nucleotide position 5149, causing the cysteine (C) at amino acid position 1717 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004540600 | SCV004780166 | uncertain significance | CDH23-related disorder | 2023-11-22 | no assertion criteria provided | clinical testing | The CDH23 c.5149T>A variant is predicted to result in the amino acid substitution p.Cys1717Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.017% of alleles in individuals of African descent in gnomAD. A different nucleotide substitution affecting the same amino acid (p.Cys1717Arg) has been reported in a hearing loss cohort (Table S4, Sloan-Heggen et al. 2015. PubMed ID: 26445815). At this time, the clinical significance of the c.5149T>A (p.Cys1717Ser) variant is uncertain due to the absence of conclusive functional and genetic evidence. |